Tag: Photoimmunotherapy

Modulight Spotlights: LASER-SHARP RESEARCH – February 2026

Laser-sharp Research / antibodies, Cancer therapy, laser therapy, laser-sharp research, ML7710, next generation therapies, peptides, Photoimmunotherapy, tumor / February 27, 2026

Modulight Spotlights: LASER-SHARP RESEARCH – February 2026 This month, we are highlighting promising work by Professor Hirofumi Hanaoka’s team at Kansai Medical University, Photo-ImmunoTherapy Research Institute. They developed a novel peptide-based photoimmunotherapy drug that targets PD-L1, which is expressed on many types of cancer cells. Preclinical experiments showed significant suppression of tumor growth and an [...]

Modulight Spotlights: LASER-SHARP RESEARCH – February 2026 Read More »

Modulight Spotlights: LASER-SHARP RESEARCH – January 2026

Laser-sharp Research / apoptosis, BPD, cancer, ferroptosis, in vitro, in vivo, laser-sharp research, light activation, ML6600, ovarian cancer, Photoimmunotherapy, photosensitizer / January 28, 2026

Modulight Spotlights: LASER-SHARP RESEARCH – January 2026 The highlight of the month goes to teams of researchers led by Prof. Imran Rizvi at University of North Carolina at Chapel Hill. Their latest publication shows that certain light-activated therapy with BPD photosensitizer and ML6600 laser can induce ferroptosis-like cell death, including formation of lipid peroxides, in

Modulight Spotlights: LASER-SHARP RESEARCH – January 2026 Read More »

Modulight Spotlights: LASER-SHARP RESEARCH – November 2025

Laser-sharp Research / cancer, chemotherapy, drug delivery, glioblastoma, in vitro, laser-sharp research, ML8500, multidrug resistance, photoactivated chemotherapy, Photoimmunotherapy, preclinical, therapy resistance, tumor, University of Maryland, verteporfin / November 19, 2025

Modulight Spotlights: LASER-SHARP RESEARCH – November 2025 We are delighted to highlight new exciting study by Rahman et al. from Dr. Huang-Chiao Huang’s lab at University of Maryland. Multidrug resistance remains a significant barrier to successful chemotherapy outcomes for cancer patients, often caused by active pumping of chemotherapeutics outside of cancer cells. Hence, the team

Modulight Spotlights: LASER-SHARP RESEARCH – November 2025 Read More »

Modulight Spotlights: LASER-SHARP RESEARCH – October 2025

Laser-sharp Research / breast cancer, immunotherapy, laser-sharp research, ML7710, myeloma, oral cancer, Photoimmunotherapy, preclinical, T cells / October 29, 2025

This month we are highlighting exciting findings by S. Takao et al. from Hisataka Kobayashi’s lab at the National Cancer Institute, NIH. Published in Cancer Letters, the study shows that near-infrared photoimmunotherapy can destroy cancer cells by targeting intercellular adhesion molecule-1.

Modulight Spotlights: LASER-SHARP RESEARCH – October 2025 Read More »

Modulight Spotlights: LASER-SHARP RESEARCH – September 2025

Laser-sharp Research / cancer, immunotherapy, in vitro, in vivo, laser-sharp research, ML7710, noveltherapies, Photoimmunotherapy, targeted therapy / September 2, 2025

Published in journal Cancer Medicine, the study shows that the therapeutic effect of photoimmunotherapy is highly dependent on the used light irradiation conditions. Application of the ML7710 medical laser at different durations and powers resulted in highest anti-tumor effect with increased light dose but lowering fluence rate below what is currently used in clinic.

Modulight Spotlights: LASER-SHARP RESEARCH – September 2025 Read More »

Interleukin 15 (IL15)-based near-infrared photoimmunotherapy

Scientific papers / 690 nm, in vitro, in vivo, interleukin15, IR700, light activation, ML7710, National Cancer Institute, NIH, NIR, Photoimmunotherapy, PIT, tumor / August 31, 2025

Published in: Cancer Immunology, Immunotherapy Authors: Motofumi Suzuki, Aki Furusawa, Hiroshi Yamamoto, Makoto Kano, Miyu Kano, Seiichiro Takao, Shuhei Okuyama, Peter L. Choyke, Hisataka Kobayashi

Interleukin 15 (IL15)-based near-infrared photoimmunotherapy Read More »

Modulight Spotlights: LASER-SHARP RESEARCH – August 2025

Laser-sharp Research / breast cancer, cancer, immunotherapy, in vitro, in vivo, laser-sharp research, ML7710, NIH, Photoimmunotherapy, targeted therapy / August 18, 2025

Laser-sharp research of the month is by Furusawa et al. at Center for Cancer Research, National Cancer Institute, USA. The discovery, published in Annals of Medicine, showed the potential of photoimmunotherapy for treating breast cancer. To expand the usefulness of photoimmunotherapy outside the clinically approved head & neck indication, the new therapy targeted epithelial cell adhesion molecule in breast cancer.

Modulight Spotlights: LASER-SHARP RESEARCH – August 2025 Read More »

EpCAM-targeted near-infrared photoimmunotherapy (NIR-PIT) for the treatment of breast cancer

Scientific papers / 690 nm, breast cancer, in vitro, in vivo, IR700, ML7710, NIH, NIR, Photoimmunotherapy / August 12, 2025

Published in: Annals of Medicine Authors: Aki Furusawa ,Seiichiro Takao, Motofumi Suzuki, Makoto Kano, Hiroshi Yamamoto, Miyu Kano, Peter Choyke, Hisataka Kobayashi

EpCAM-targeted near-infrared photoimmunotherapy (NIR-PIT) for the treatment of breast cancer Read More »

Modulight Spotlights: LASER-SHARP RESEARCH – April 2025

Laser-sharp Research / drug delivery, imaging, in vitro, laser-sharp research, light activation, ML6600, nanoparticles, Photodynamic therapy, Photoimmunotherapy, verteporfin / April 30, 2025

Gokalp et al. from University of Massachusetts and Tufts University constructed an innovative liquid metal nanoparticle platform, which has tumor cell targeting and enhanced encapsulation of verteporfin. Charactierization in vitro with the help of ML6600 laser showed effective in vitro phototoxicity.

Modulight Spotlights: LASER-SHARP RESEARCH – April 2025 Read More »